The optimism following Elliott's presentation initially lifted shares; however, Norwegian's lackluster fourth-quarter ...

If The Times had published Progress editions a century ago, the 1926 version would likely have featured an update on the work the Chicago South Shore & South Bend Railroad’s ...

First Trust Enhanced Short Maturity ETF (FTSM) offers a way to earn more than cash without taking on meaningful duration risk ...

PODIUM-03 shows retifanlimab plus carboplatin/paclitaxel boosts response and survival, reshaping first-line care for advanced anal cancer. This segment highlights the ...

The March/April 2026 issue of Supply Chain Management Review examines how supply chain leaders are managing supplier risk, circular supply chain design, AI-driven retail planning, CPG network ...

Adam M. Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh; Laura Huppert, MD, assistant professor at the University of California San Francisco; and Tiffany A. Traina, MD, breast ...

Japan’s K Line is bringing its ship management units together under one new holding company. The giant Tokyo-listed shipowner has formed K Line Ship Management Holdings (KLSM-H) as a response to a ...

Wealth management has reached an inflection point — not driven by another technology cycle, but by the limits of its traditional operating model. Fee compression continues to erode margins. Advisors ...

Elliott Management recently disclosed a 10% stake in Norwegian Cruise Lines (NCLH) in what will likely be a campaign by the activist investor to effect changes in the company’s board and reverse years ...

Elliott Investment Management disclosed a stake exceeding 10% in Norwegian Cruise Line (NCLH) and demands board overhaul. Norwegian Cruise Line declined 9.68% over five years while Royal Caribbean ...

Team Canada players saw their line combinations for the first time on Sunday night. Gregory Shamus / Getty Images MILAN — About an hour before the Canadian men’s hockey team stepped on the ice for ...

NCCN upgrades Trodelvy to category 1 preferred first-line therapy for metastatic TNBC with CPS <10 and no germline BRCA1/2 mutation. For PD-L1–positive metastatic TNBC (CPS ≥10), Trodelvy plus ...